Eledon Pharmaceuticals, Inc.
ELDN
$3.54
-$0.16-4.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.15% | -8.75% | 33.36% | 38.43% | 48.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.32% | 17.96% | 53.80% | 87.40% | 81.65% |
| Operating Income | -11.32% | -17.96% | -53.80% | -87.40% | -81.65% |
| Income Before Tax | -319.57% | -27.49% | -266.27% | 113.89% | 85.61% |
| Income Tax Expenses | -91.88% | -91.88% | -- | -- | -- |
| Earnings from Continuing Operations | -310.26% | -26.07% | -268.26% | 113.49% | 85.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -310.26% | -26.07% | -268.26% | 113.49% | 85.28% |
| EBIT | -11.32% | -17.96% | -53.80% | -87.40% | -81.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -125.74% | 47.28% | 17.67% | 127.71% | 92.44% |
| Normalized Basic EPS | -184.31% | 43.29% | 19.45% | 119.55% | 94.00% |
| EPS Diluted | 67.70% | 82.72% | 68.24% | 67.10% | 47.16% |
| Normalized Diluted EPS | -114.80% | 48.19% | 24.70% | 116.57% | 92.06% |
| Average Basic Shares Outstanding | 50.07% | 68.36% | 94.37% | 107.68% | 111.29% |
| Average Diluted Shares Outstanding | 47.91% | 65.36% | 90.04% | 110.34% | 114.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |